These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34428046)

  • 1. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
    El-Khateeb E; Achour B; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Mol Pharm; 2021 Sep; 18(9):3563-3577. PubMed ID: 34428046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaling Factors for Clearance in Adult Liver Cirrhosis.
    El-Khateeb E; Achour B; Scotcher D; Al-Majdoub ZM; Athwal V; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2020 Dec; 48(12):1271-1282. PubMed ID: 32978222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes.
    El-Khateeb E; Al-Majdoub ZM; Rostami-Hodjegan A; Barber J; Achour B
    Drug Metab Dispos; 2021 Aug; 49(8):610-618. PubMed ID: 34045218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.
    Prasad B; Bhatt DK; Johnson K; Chapa R; Chu X; Salphati L; Xiao G; Lee C; Hop CECA; Mathias A; Lai Y; Liao M; Humphreys WG; Kumer SC; Unadkat JD
    Drug Metab Dispos; 2018 Jul; 46(7):943-952. PubMed ID: 29695616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Tissue Abundance of Membrane-Bound Drug Metabolizing Enzymes and Transporter Proteins by Global Proteomics.
    Singh DK; Ahire D; Davydov DR; Prasad B
    Drug Metab Dispos; 2024 Oct; 52(11):1152-1160. PubMed ID: 38641346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States.
    Sharma S; Suresh Ahire D; Prasad B
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects.
    Vasilogianni AM; Al-Majdoub ZM; Achour B; Peters SA; Rostami-Hodjegan A; Barber J
    Br J Clin Pharmacol; 2022 Feb; 88(4):1811-1823. PubMed ID: 34599518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis.
    Vasilogianni AM; Al-Majdoub ZM; Achour B; Annie Peters S; Barber J; Rostami-Hodjegan A
    Clin Pharmacol Ther; 2022 Sep; 112(3):699-710. PubMed ID: 35510337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Characterization of Clinically Relevant Drug-Metabolizing Enzymes and Transporters in Rat Liver and Intestinal Segments for Applications in PBPK Modeling.
    Sharma S; Singh DK; Mettu VS; Yue G; Ahire D; Basit A; Heyward S; Prasad B
    Mol Pharm; 2023 Mar; 20(3):1737-1749. PubMed ID: 36791335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.
    Wang L; Collins C; Kelly EJ; Chu X; Ray AS; Salphati L; Xiao G; Lee C; Lai Y; Liao M; Mathias A; Evers R; Humphreys W; Hop CE; Kumer SC; Unadkat JD
    Drug Metab Dispos; 2016 Nov; 44(11):1752-1758. PubMed ID: 27543206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis.
    Vasilogianni AM; Achour B; Scotcher D; Peters SA; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2021 Jul; 49(7):563-571. PubMed ID: 33980603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation.
    Ladumor MK; Thakur A; Sharma S; Rachapally A; Mishra S; Bobe P; Rao VK; Pammi P; Kangne H; Levi D; Balhara A; Ghandikota S; Joshi A; Nautiyal V; Prasad B; Singh S
    Sci Rep; 2019 Jul; 9(1):9709. PubMed ID: 31273226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease.
    Vasilogianni AM; El-Khateeb E; Al-Majdoub ZM; Alrubia S; Rostami-Hodjegan A; Barber J; Achour B
    J Proteomics; 2022 Jul; 263():104601. PubMed ID: 35537666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
    Kalam MN; Rasool MF; Alqahtani F; Imran I; Rehman AU; Ahmed N
    Drug Des Devel Ther; 2021; 15():1195-1211. PubMed ID: 33762817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD).
    Adiwidjaja J; Spires J; Brouwer KLR
    Pharm Res; 2024 Mar; 41(3):441-462. PubMed ID: 38351228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
    Jamwal R; de la Monte SM; Ogasawara K; Adusumalli S; Barlock BB; Akhlaghi F
    Mol Pharm; 2018 Jul; 15(7):2621-2632. PubMed ID: 29792708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
    Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of
    Franchetti Y; Nolin TD
    J Pharmacol Exp Ther; 2019 Oct; 371(1):151-161. PubMed ID: 31399494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental Expression of Drug Transporters and Conjugating Enzymes Involved in Enterohepatic Recycling: Implication for Pediatric Drug Dosing.
    Thakur A; Subash S; Ahire D; Prasad B
    Clin Pharmacol Ther; 2024 Dec; 116(6):1615-1626. PubMed ID: 39160670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.